- Home
- CBRE vs BIIB Comparison
CBRE vs BIIB Comparison
Compare CBRE & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CBRE | BIIB |
|---|---|---|
| Founded | 1906 | 1978 |
| Country | United States | United States |
| Employees | 44000 | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.5B | 34.5B |
| IPO Year | 2001 | 1996 |
Fundamental Metrics
Financial Performance| Metric | CBRE | BIIB |
|---|---|---|
| Price | $131.69 | $252.47 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 36 |
| Target Price | $178.58 | ★ $243.98 |
| AVG Volume (30 Days) | ★ 1.6M | 1.1M |
| Earning Date | 10-22-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.61 | N/A |
| EPS | 1.77 | ★ 2.15 |
| Revenue | ★ $40,550,000,000.00 | $9,890,600,000.00 |
| Revenue This Year | $16.05 | $5.54 |
| Revenue Next Year | $10.89 | $1.91 |
| P/E Ratio | ★ $75.83 | $112.34 |
| Revenue Growth | ★ 13.37 | 2.22 |
| 52 Week Low | $121.69 | $138.00 |
| 52 Week High | $174.27 | $244.65 |
Technical Indicators
Market Signals| Indicator | CBRE | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 45.55 | 75.43 |
| Support Level | $126.02 | $184.50 |
| Resistance Level | $138.11 | N/A |
| Average True Range (ATR) | 4.19 | 6.89 |
| MACD | 0.82 | 2.17 |
| Stochastic Oscillator | 53.96 | 99.26 |
Price Performance
Historical ComparisonAbout CBRE CBRE Group Inc
CBRE Group provides a wide range of real estate services to owners, occupants, and investors worldwide, including leasing, property and project management, and capital markets advisory. CBRE's investment management arm managed over $155 billion (at year-end 2025) for clients across diverse public and private real estate strategies.
About BIIB Biogen Inc.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).